Overview
Bone Marrow Failure Syndromes
General Hematology
Current Appointments & Affiliations
Professor of Pediatrics
·
2022 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Professor in Medicine
·
2022 - Present
Medicine, Hematology,
Medicine
Recent Publications
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH study.
Journal Article Blood Adv · December 3, 2025 Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH), a hyperinflammatory syndrome, has poor prognosis and no standard therapy. Emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon-gamma, is appr ... Full text Link to item CiteEltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
Journal Article JAMA · November 25, 2025 IMPORTANCE: Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia ... Full text Link to item CiteEltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial.
Journal Article Blood Adv · August 12, 2025 Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to <18 years) with re ... Full text Link to item CiteRecent Grants
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2025 - 2027Achieving Understanding of the Natural history of sickle cell Trait (AUNT)
ResearchCollaborating Investigator · Awarded by National Alliance for Sickle Cell Centers · 2024 - 2026A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2019 - 2026View All Grants
Education, Training & Certifications
University of Medicine and Dentistry of New Jersey ·
2003
M.D.